Navigation Links
New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV

Phase III clinical trial provides hope that HIV patients can live longer lives

PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A new investigational drug used in combination with a second newer agent has proven to be effective in fighting drug-resistant HIV, according to a Lancet article to be published in its July 7th special HIV/AIDS issue.

The multinational phase III clinical trial, which involved 18 nations and more than 30 centers in the United States, is the first trial to offer patients infected with resistant HIV the potential of receiving two investigational new drugs together to fight the disease. The two drugs, amongst the most powerful agents to fight the disease to date, are TMC125 (etravirine) and TMC114 (darunavir, also known as Prezista), both made by Tibotec (a Johnson & Johnson company), the sponsor of the ongoing trial. The data will be presented for the first time during the July 22nd-25th International AIDS Society conference in Sydney, Australia by the lead investigator in the trial, Dr. Adriano Lazzarin of Italy.

"This study is one of the most significant worldwide HIV/AIDS clinical trials in recent years. It showed that when the two drugs are used in combination, there is a good chance HIV can be very effectively controlled in patients who have advanced, multi-drug-resistant HIV," said William J. Towner, MD, Kaiser Permanente Southern California, a co-author of the Lancet article. Kaiser Permanente had the highest number of enrollees in the study from the United States.

Dr. Towner said that the ongoing 'DUET-2' trial -- large, randomized, and placebo controlled -- is the pivotal registration and efficacy trial for TMC125 (it is in a class of HIV drugs called non-nucleoside reverse transcriptase inhibitors [NNRTI]). The Lancet study found that at the 24th week, patients who received TMC125 in combination with TMC114 achieved superior virological suppression than t hose who received TMC114 alone. The results from the phase III clinical trial will be submitted to regulatory authorities, which must grant their approval before the new drug can be publicly available.

For the DUET trial, Kaiser Permanente enrolled the most patients of all the participating centers in the United States and was the third largest enroller in the world. Nationally, Kaiser Permanente is the second largest provider of HIV care, caring for more than 17,000 HIV infected patients. More than one million Americans are currently living with HIV, and the HIV/AIDS virus has killed more than 524,000 Americans to date.

Dr. Towner added that the trial is most uniquely significant because it utilized another novel HIV medication, TMC114 (in a class of HIV drugs called protease inhibitors; TMC114 was still an investigational agent when the trial started).

According to Dr. Towner, "Treating a resistant virus with two active agents has been a mantra in HIV care for quite some time. Adding only one active agent to a patient experiencing drug failure usually results in the rapid, predictable development of resistance to that agent. Very seldom do patients get the chance to receive two potent new investigational agents in one clinical trial. The DUET trials were one of the first to give the patients such a chance."

Dr. Towner is the Medical Director of Kaiser Permanente Southern California's HIV/AIDS Research Trials (HART) and the Kaiser Permanente Southern California Regional HIV/AIDS Physician Coordinator. The HART Program was founded in order to ensure that Kaiser Permanente HIV patients with advanced disease have access to the latest drugs.

Kaiser Permanente is America's leading integrated health plan. Founded in 1945, it is a not-for-profit, group practice program headquartered in Oakland, Calif. Kaiser Permanente serves more than 8.7 million members in nine states and the District of Columbia. Today it encompasses the not-for-profi t Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and their subsidiaries, and the for-profit Permanente Medical Groups. Nationwide, Kaiser Permanente includes approximately 156,000 technical, administrative and clerical employees and caregivers, and 13,000 physicians representing all specialties. For more Kaiser Permanente news, visit the KP News Center at: http://xnet.kp.org/newscenter

CONTACT: Danielle Cass, +1-510-267-5354, or Calvin Naito, +1-626-405-5788,both of Kaiser Permanente

Web site: http://www.kaiserpermanente.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
6. Major Manufacturer of Unapproved and Adulterated Drugs
7. Global Rabies Treatment May be Possible with NanoViricides Drugs
8. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... 2017  Xyntek Inc. has announced another milestone in their continued growth and ... meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite 1528, ... Xyntek's recently ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... clinical and commercial support services market) has entered into an agreement on September ... , The PGSD is the first private Dental School to launch an ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic ... National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, ... when Athletic Trainers are acknowledged by their peers with accolades and highly prestigious ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... ... ... Health & Safety Institute (HSI) is offering discounted pricing on its Summit ... now until November 30, 2017 to assist with the clean-up efforts from hurricanes Harvey ... and government agencies – whether or not they will be directly involved in the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED Ezekiel's Plan for Freedom ... Freedom from ADDICTION” is the creation of published author, Bill Miller. Bill ... homeless services, including more than a decade of addiction to prescription drugs. ...
Breaking Medicine News(10 mins):